Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04743141 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
A Phase 3 study of Acute Treatment of Migraine, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT04743141: Recruiting Phase 3 study of Acute Treatment of Migraine, sponsored by Pfizer.
NCT04743141 is a Phase 3 study of Acute Treatment of Migraine that is actively recruiting participants, run by Pfizer. The registered enrollment target is 600 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04743141, a Phase 3 study of Acute Treatment of Migraine, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Primary Outcome
To evaluate the safety and tolerability of rimegepant in children and adolescents (6 to \< 18 years of age).
Conditions Studied
Interventions
- DRUG Rimegepant (PF-07899801)
Study Locations (20)
California
- Advanced Research Center, Inc. - Anaheim
- ProScience Research Group - Culver City
- Neuro-Pain Medical Center - Fresno
- Regents of the University of California (UC San Diego) - La Jolla
- Adult & Child Neurology Medical Associates - Long Beach
- Memorialcare Miller Children's & Women's Hospital Long Beach - Long Beach
- Velocity Clinical Research - North Hollywood - North Hollywood
- The Neurology Group - Pomona
- UC Davis Medical Center, Investigational Drug Service (IDS) Pharmacy - Sacramento
- University of California, Davis Clinical and Translational Science Center Clinical Research Center - Sacramento
- University of California, Davis Midtown Clinic - Sacramento
- Velocity Clinical Research- Banning - San Bernardino
- Pacific Clinical Research Management Group LLC - Upland
- Sunwise Clinical Research - Walnut Creek
Colorado
- Children's Hospital Colorado- Investigational Drug Services - Aurora
- Children's Hospital Colorado - Aurora
- Colorado Springs Neurological Associates, PC - Colorado Springs
- Colorado Springs Neurological Associates, PC - Colorado Springs
Arizona
- Perseverance Research Center, LLC - Scottsdale
- Physicians Research Group - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2030-07-31 |
| Phase | Phase 3 |
What NCT04743141 shows while recruiting
NCT04743141 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Acute Treatment of Migraine appearing as the primary indexed condition, and to 1 intervention - of which Rimegepant (PF-07899801) is the first listed.
NCT04743141 names 20 study sites across 3 states, led by California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT04743141 about?
NCT04743141 is a clinical study titled "Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine". The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
What is the current status of trial NCT04743141?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2021-04-28. Estimated completion is 2030-07-31.
What conditions does trial NCT04743141 study?
This clinical trial studies the following conditions: Acute Treatment of Migraine.
What interventions are being tested in trial NCT04743141?
The interventions under investigation include: Rimegepant (PF-07899801) (DRUG).
Who is sponsoring clinical trial NCT04743141?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04743141 being conducted?
This trial has 20 study locations across Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Treatment of Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04743141's enrollment target sits among peer trials
600 608th of 2000 higher than 1,364 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI